Home » Topics » Disease categories and therapies » Respiratory

Respiratory
RSS

Two series of inhibitors of alpha4beta1-mediated cell adhesion claimed by Aventis

Dec. 18, 2000

Nortran's phase II clinical trial of CP1 fails to meet primary endpoint

Dec. 18, 2000

Orally active HNE inhibitor in clinical trials at Ono

Dec. 18, 2000

Potent, long-acting, orally active M3 antagonist selected for clinical development at Banyu

Dec. 15, 2000

TRK-851: clinical trials under way for selective DOP antagonist with antitussive activity

Dec. 15, 2000

Schering-Plough seeks FDA approval for new formulations of desloratadine

Dec. 15, 2000

Alliance completes enrollment in phase II/III trial of LiquiVent

Dec. 15, 2000

Dual Tx synthase and 5-LO inhibitors synthesized at Nikken

Dec. 14, 2000

New Claritin formulation receives FDA marketing approval

Dec. 14, 2000

Kaken presents dual LTD4 and TxA2 antagonist with promising antiasthmatic profile

Dec. 13, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 5, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...